. 2014 Dec 13;12:346. doi: 10.1186/s12967-014-0346-3

Table 1.

Summary of antibodies and virus strains used in the study.

*A. mAbs used*	Target on Env
4E10	MPER*
2F5	MPER*
2G12	V3 glycans†
b12	CD4bs†
PG9	V1/V2 loop†
PG16	V1/V2 loop†
*B. env strains used for Pseudovirus*	Clade	Subject identifier	Accession Number	Gender	Mode of Transmission	Fiebig Stage ^b
SF162	B	N.A.	EU123924	Male	N/A	VI
AC10.0.29	B	AC10.0	AY835446	Male	MSM^a	III
REJO4541.67	B	REJO4541	AY835449	Male	HSX	II
RHPA4259.7	B	RHPA4256	AY835447	Female	HSX	≤ V
THRO4156.18	B	THRO4156	AY835448	Male	MSM	II
*C. IMC of T/F strains*
CH040.c	B	700010040	JN944939	Male	MSM	T/F IMC^c
CH058.c	B	700010058	JN944940	Male	MSM	T/F IMC^c
CH077.t	B	700010077	JN944941	Male	MSM	T/F IMC^c
REJO.c	B	REJO4541	JN944943	Male	HSX	T/F IMC^c
RHPA.c	B	RHPA4256	JN944944	Female	HSX	T/F IMC^c
THRO.c	B	THRO4156	JN944947	Male	MSM	T/F IMC^c

A. Monoclonal antibodies used and respective target epitope on Env; * on gp41 and † on gp120

B-C. Virus used: Pseudovirus (B) and Transmitted/Founders (T/F) IMCs (C).

^aMSM, men who have sex with men; HSX, heterosexual.

^bThe stage of HIV-1 infection, as defined by Fiebig et al. [15], at which samples were obtained.

^cT/F IMCs represent the genomes of the strains that initiated clinical infection in the respective subjects. For detailed description, see C. Ochsenbauer et al., [2].